Augmenix announces positive SpaceOAR hydrogel clinical trial results

Augmenix, which manufactures absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, announced the 3-year results from the SpaceOAR System Prostate Cancer US Pivotal Clinical Trial. The study results, presented at ASTRO, demonstrated significantly lower rectal toxicity and higher patient quality of life scores when the SpaceOAR System was applied prior to radiotherapy as compared to the trial control patients.
Business Wire